- IMS Health May 2015 comments on patient access to oncology drugs
- Switzerland pressures Colombia to deny compulsory license on imatinib
- 17 WTO Members (Brazil, China, India, Russia) submit draft Ministerial Decision on Non-Violation and Situation Complaints
- KEI briefing note on the evolution of TPP negotiating text on patentable subject matter
- Seminars on Drug Pricing: Part 3, Aidan Hollis
- KEI's second installment of TPP IP Chapter leak, includes copyright, all other provisions
- Knowledge Ecology International Leaks TPP Text on Intellectual Property
- WTO Trade Policy Review of India- EU, Japan, Switzerland and the US question India over Section 3(d) and Compulsory Licensing
- Consensus achieved at WIPO Standing Committee on the Law of Patents (SCP) on Future Work Program
- WIPO SCP22: Language on GRULAC proposal to revise 1979 WIPO Model Law for Developing Countries on Inventions
US Copyright office proposes limits on damages, injunctions, for Orphan Works, contradicting TPP languageSubmitted by James Love on 4. June 2015 - 15:51
The US Copyright Office has proposed limitations on damages and injunctions, when "orphan" copyrighted works are infringed.
Attached (here) is the October 3, 2014 version of the Draft Text, of the Intellectual Property Chapter, for the Regional Comprehensive Economic Partnership (RCEP), Free Trade Agreement, tabled by South Korea in the negotiations. (More about the RCEP here)
The next round of negotiation will be held in Kyoto, Japan from 8-12 June.
WTO TRIPS Council (February 2015): EU statement on LDC extension of transition period for pharmaceutical productsSubmitted by thiru on 3. June 2015 - 4:25
The following statement was delivered by the European Union at the February 2015 session in response to the proposal by the LDC Group Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement.
In particular, the European Union noted,
June 2015: WTO reports on India's Section 3(d) and compulsory licensing provisions - WTO Trade Policy Review - IndiaSubmitted by thiru on 2. June 2015 - 7:29
On 2 June 2015 and 4 June 2015, the World Trade Organization (WTO) is conducting a trade policy review of India. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the "Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures" (Source: WTO, Trade Policy Reviews: Brief Introduction).
For any of you in Bucharest this weekend at the EASL conference on liver disease, KEI Europe will host a side event on access to affordable HCV medicines on Saturday morning.
Pathways to Widespread Access: Affordable HCV Medicines in Romania
Date: 10:00-12:00 Saturday, 30 May 2015
Venue: Novotel Bucharest City Centre, Conference Room Lyon (Mezzanine Floor)
A Panel Discussion:
Peter Beyer, World Health Organization (WHO). Access to Medicines and Intellectual Property Rights
On Thursday, May 21, 2015, KEI and KEI Europe hosted a side event at the 68th World Health Assembly on compulsory licensing of patents on drugs, vaccines, and diagnostic tests. The event was graciously hosted by UNAIDS in the Kofi Annan room.
The TPP, following a plethora of other trade agreements involving the United States, the European Union and Japan as trading partners, seeks to expand and extend drug monopolies, by requiring lower standards for the grant of patents, extensions of patent terms, exclusive rights in test data, among other measures. These proposals and polices are designed to have the predictable effect of making drug prices higher.
WHA68: Statement of HAI/KEI on Follow-up to 2014 HLM on comprehensive review + assessment of prevention and control of NCDsSubmitted by thiru on 26. May 2015 - 2:22
On Tuesday, 26 May 2015, the following statement was delivered in Committee B of the 68th World Health Assembly on behalf of Stichting Health Action International and Knowledge Ecology International on the topic: Follow-up to the 2014 high-level meeting of the United Nations General Assembly to undertake a comprehensive review and assessment of the progress achieved in the prevention and control of noncommunicable diseases.
May 21, 2015- Agenda for KEI/KEI Europe panel on Compulsory licensing of patents on drugs, vaccines and diagnostic testsSubmitted by thiru on 20. May 2015 - 9:36
Compulsory licensing of patents on drugs, vaccines and diagnostic tests
Knowledge Ecology International (KEI) and Knowledge Ecology International Europe (KEI Europe):
DATE: Thursday, 21 May 2015
VENUE: Kofi Annan Room, UNAIDS, Avenue Appia 20
- Ellen 't Hoen, Medicines, Law and Policy
WHA68: Greek Minister of Health - Panagiotis Kouroumplis - calls for de-linkage of R&D from the price of health technologiesSubmitted by thiru on 18. May 2015 - 16:15
On Monday, 18 May 2015, the Greek Minister of Health, Panagiotis Kouroumplis, delivered the following speech at the World Health Assembly in Geneva, explicitly calling for the de-linkage of the "cost of R&D from the final price of medicines" while highlighting the deleterious effects of austerity measures eroding public health systems, counter to the theme of WHA68, "Resilient Health Systems".
Here is his speech in full:
Madam Director General, dear colleagues, excellencies, ladies and gentlemen
This is a briefing note prepared for TPP negotiators, addressing a single but important issue, the standards for issuing compulsory licenses in the TPP.
Attached is the text of a letter sent by Senator Bernie Sanders to Robert A. McDonald, the Secretary, U.S. Department of Veterans Affairs, asking the Secretary "to use your authority as Secretary of Veterans Affairs to break the patents on Hepatitis C medications for the treatment of veterans suffering with the disease."
UACT Comments to DHHS on WHA: Agenda Item 13.4 Assessment of Progress in Prevention & Control of NCDsSubmitted by Manon Ress on 8. May 2015 - 14:35
To prepare for the upcoming 68th World Health Assembly (WHA), the U.S. Department of Health & Human Services held a Stakeholder Listening Session on Friday, May 8, 2015, from 10:30am - 12pm in the HHS Humphrey Building - 200 Independence Ave, SW, Washington, DC 20201. All Agenda items for the upcoming WHA are here:
KEI Comments to DHHS on WHA Agenda 17.5 (Global Strategy and Plan of Action on Public Health, Innovation and IP)Submitted by KEI Staff on 8. May 2015 - 9:58
On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here.
KEI comments to DHHS on WHA agenda 17.4, the Consultative Expert Working Group on Research and DevelopmentSubmitted by James Love on 8. May 2015 - 9:47
Re: 17.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Document A68/34
My name is James Love, from Knowledge Ecology International. I wanted to discuss the negotiations on new approaches to funding medical R&D.
I will begin with the much delayed discussions about a WHO R&D treaty, which are supposed to resume in 2016.
We have suggestions for some changes in the discussion, to move things forward.